Please use this identifier to cite or link to this item:
|Title:||Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study||Authors:||Roger, Simon D ;Spinowitz, B.S.;Fishbane, Steven ;Pergola, P.E.;Lerma, E.V.;Butler, J.;von Haehling, S.;Adler, S.H.;Zhao, J.;Singh, B.;Lavin, P.T.;McCullough, P.A.;Kosiborod, M.;Packham, D.||Affliation:||Central Coast Local Health District
|Issue Date:||Jun-2019||Source:||14(6):798-809||Journal title:||Clinical Journal of the American Society of Nephrology||Department:||Renal||Abstract:||BACKGROUND AND OBJECTIVES: Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate-associated restoration and maintenance of normokalemia and adverse events were evaluated in a two-part, open label, phase 3 trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In the correction phase, adult outpatients with plasma potassium >/=5.1 mmol/L (i-STAT Point-of-Care) received sodium zirconium cyclosilicate 10 g three times daily for 24-72 hours until normokalemic (potassium =3.5-5.0 mmol/L). Qualifying participants entered the </=12-month maintenance phase and received sodium zirconium cyclosilicate 5 g once daily titrated to maintain normokalemia without dietary or medication restrictions. Prespecified primary end points were restoration of normal serum potassium values (3.5-5.0 mmol/L) during the correction phase and maintenance of serum potassium </=5.1 mmol/L during the maintenance phase. Adverse events were assessed throughout. RESULTS: Of 751 participants, 746 (99%) achieved normokalemia during the correction phase (mean serum potassium =4.8 mmol/L; 95% confidence interval, 4.7 to 4.8) and entered the maintenance phase; 466 (63%) participants completed the 12-month trial. Participants were predominantly white, men, and age >/=65 years old; 74% had an eGFR<60 ml/min per 1.73 m(2), and 65% used renin-angiotensin-aldosterone system inhibitors. Mean time on sodium zirconium cyclosilicate was 286 days. Mean daily sodium zirconium cyclosilicate dose was 7.2 g (SD=2.6). Over months 3-12, mean serum potassium was 4.7 mmol/L (95% confidence interval, 4.6 to 4.7); mean serum potassium values </=5.1 and </=5.5 mmol/L were achieved by 88% and 99% of participants, respectively. Of 483 renin-angiotensin-aldosterone system inhibitor users at baseline, 87% continued or had their dose increased; 11% discontinued. Among 263 renin-angiotensin-aldosterone system inhibitor-naive participants, 14% initiated renin-angiotensin-aldosterone system inhibitor therapy. Overall, 489 (66%) participants experienced adverse events during the maintenance phase, and 22% experienced a serious adverse event. Of eight (1%) deaths, none were considered related to sodium zirconium cyclosilicate. Nine (1%) and 34 (5%) participants experienced serum potassium <3.0 and 3.0-3.4 mmol/L, respectively. CONCLUSIONS: After achieving normokalemia, individualized once daily sodium zirconium cyclosilicate was associated with maintenance of normokalemia without substantial renin-angiotensin-aldosterone system inhibitor changes for </=12 months.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1490||DOI:||10.2215/cjn.12651018||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/31110051||ISSN:||1555-9041||Publicaton type:||Journal Article||Keywords:||Kidney Disease
|Study or Trial:||Clinical Trial|
|Appears in Collections:||Renal Medicine|
Show full item record
checked on Feb 2, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.